Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cerebral hemorrhage with amyloidosis (HCHWA), Icelandic type is a form of HCHWA characterized by an age of onset of 20-30 years, systemic amyloidosis and recurrent lobar intracerebral hemorrhages.
Features include: Cerebral hemorrhage, Stroke, Progressive loss of mental abilities (dementia), and Intracranial hemorrhage and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Cerebral hemorrhage, Stroke, Progressive loss of mental abilities (dementia) |
Heart and blood vessels | 2 | Stroke, Intracranial hemorrhage |
CST3 encodes cystatin C (146 aa). As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity Highest expression in Brain Putamen basal ganglia (653.3 TPM) and Brain Caudate basal ganglia (619.9 TPM).
ACys amyloidosis is associated with mutations in the CST3 gene on chromosome 20.
The CST3 protein participates in Variant cystatin-C pathway.
CST3 is classified as a druggable target (Druggable Genome, Enzyme, and Protease Inhibitor categories) with score 1.3.
Genetic testing for CST3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for ACys amyloidosis has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
13 clinical trials registered, 7 recruiting. Interventions under study include other interventions, drug therapy, and medical devices. Pipeline includes 1 PHASE3, 4 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06933212](https://clinicaltrials.gov/study/NCT06933212) | Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. | — | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
[NCT06714097](https://clinicaltrials.gov/study/NCT06714097) | Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project) | NA | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
[NCT05734378](https://clinicaltrials.gov/study/NCT05734378) | Prognosis of Cerebral Small Vessel Disease | — | Insel Gruppe AG, University Hospital Bern | RECRUITING |
[NCT07026994](https://clinicaltrials.gov/study/NCT07026994) | Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage | PHASE2 | Huashan Hospital | RECRUITING |
[NCT07250035](https://clinicaltrials.gov/study/NCT07250035) | Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy | PHASE3 | Beijing Tiantan Hospital | RECRUITING |
206 publications have been identified in PubMed for ACys amyloidosis. Research spans Review / Meta-Analysis (36%), Basic Science / Preclinical (21%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 75 | 36% |
Laboratory research | 43 | 21% |
Disease patterns and progression | 28 | 14% |
Testing and diagnosis research | 23 | 11% |
Patient case studies | 15 | 7% |
New treatment approaches | 8 |
Marzoughi S (2026). [PMID: 41608814](https://pubmed.ncbi.nlm.nih.gov/41608814/). *Stroke*. [Clinical Trial Publication]
Singh V (2026). [PMID: 41549419](https://pubmed.ncbi.nlm.nih.gov/41549419/). *Alzheimers Dement*. [Basic Science / Preclinical]
Wang D (2026). [PMID: 41559482](https://pubmed.ncbi.nlm.nih.gov/41559482/). *J Neurol*. [Review / Meta-Analysis]
Su Y (2026). [PMID: 41580571](https://pubmed.ncbi.nlm.nih.gov/41580571/). *Acta Neuropathol*. [Case Report / Case Series]
Fastenau C (2026). [PMID: 40958354](https://pubmed.ncbi.nlm.nih.gov/40958354/). *Brain Pathol*. [Basic Science / Preclinical]
Panteleienko L (2026). [PMID: 40970476](https://pubmed.ncbi.nlm.nih.gov/40970476/). *Ann Neurol*. [Basic Science / Preclinical]
Mehta RI (2026). [PMID: 41566952](https://pubmed.ncbi.nlm.nih.gov/41566952/). *Brain*. [Epidemiology / Natural History]
Chen S (2026). [PMID: 42080669](https://pubmed.ncbi.nlm.nih.gov/42080669/). *N Engl J Med*. [Case Report / Case Series]
Greenberg SM (2026). [PMID: 42090794](https://pubmed.ncbi.nlm.nih.gov/42090794/). *N Engl J Med*. [Review / Meta-Analysis]
Ide T (2025). [PMID: 40825546](https://pubmed.ncbi.nlm.nih.gov/40825546/). *Brain and nerve = Shinkei kenkyu no shinpo*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ACys amyloidosis
Other research | 7 | 3% |
Clinical study results | 7 | 3% |